Lead-212-chelate complex (212Pb-chelate)

The Lead-212-chelate complex serves as a synthetic docking epitope in pretargeted radioimmunotherapy (PRIT) systems designed to deliver potent alpha radiation to tumor cells [1]. In this therapeutic strategy, a bispecific antibody is first administered to localize at the tumor site by binding a specific tumor-associated antigen (such as HER2, CEA, or GPA33) [2]. Once the unbound antibody has cleared from the circulation, the Lead-212-chelate complex is administered as a small-molecule hapten that is rapidly captured by the second arm of the pre-localized antibody [3]. Lead-212 (212Pb) acts as an in vivo generator of alpha particles, which possess high linear energy transfer (LET) capable of inducing lethal double-stranded DNA breaks within a short range, thereby sparing surrounding healthy tissue [1,4]. This pretargeting approach optimizes the therapeutic index by decoupling the slow pharmacokinetics of full-length antibodies from the relatively short half-life of the radioisotope [2]. The stability of the chelate, typically TCMC or DOTA derivatives, is essential to prevent the release of free lead, which can otherwise sequester in the bone or kidneys and cause significant toxicity [4]. Sources: [1] Orano Med. "AlphaRetargeting: A Pretargeting Platform." (oranomed.com) [2] Bodet-Milin, C., et al. (2024). "Pretargeted Radioimmunotherapy: A New Frontier." Frontiers in Medicine. [3] Goldenberg, D. M., et al. (2012). "Pretargeted Radioimmunotherapy: Update and Review of Mechanisms." Journal of Nuclear Medicine. [4] Chappell, L. L., et al. (2000). "Synthesis and evaluation of TCMC-based chelators for 212Pb." Nuclear Medicine and Biology.

Other names

212Pb-TCMC212Pb-DOTALead-212-labeled haptenRadiolabeled docking epitopeCapture epitopeBispecific antibody 212Pb-chelate docking epitope

Pretargeted radioimmunotherapy (PRIT) involving the localization of a bispecific antibody at the tumor site followed by the administration and capture of a radiolabeled Lead-212-chelate hapten.